Amgen Inc. v. F. Hoffmann-LaRoche LTD et al

Filing 502

DECLARATION re #498 MOTION for Summary Judgment of No Obviousness-Type Double Patenting BY HARVEY F. LODISH, Ph.D. by Amgen Inc.. (Attachments: #1 Exhibit A#2 Exhibit B#3 Exhibit C#4 Exhibit D-1#5 Errata D-2#6 Exhibit D-3#7 Errata D-4#8 Exhibit E-1#9 Exhibit E-2 (part 1)#10 Exhibit E-2 (part 2)#11 Exhibit E-3#12 Exhibit E-4#13 Exhibit E-5 (part 1)#14 Exhibit E-5 (Part 2)#15 Exhibit E-5 (part 3)#16 Exhibit E-6)(Gottfried, Michael)

Download PDF
Amgen Inc. v. F. Hoffmann-LaRoche LTD et al Doc. 502 Att. 5 Case 1:05-cv-12237-WGY Document 502-6 Filed 06/14/2007 Page 1 of 2 EXHIBIT D-2 Lodish Decl to Motion for SJ re ODP - Public Dockets.Justia.com Case 1:05-cv-12237-WGY Document 502-6 Filed 06/14/2007 Page 2 of 2 Table D-2 Original Group V Claims 55. A pharmaceutical composition comprising an effective amount of a polypeptide according to claims 1, 16, 39, 40 or 41 and a pharmaceutically acceptable diluent, adjuvant or carrier. `933 Pharmaceutical Composition Claims 9. A pharmaceutical composition comprising an effective amount a glycoprotein product effective for erythropoietin therapy according to claim 1, 2, 3, 4, 5 or 6 and a pharmaceutically acceptable diluent, adjuvant or carrier. 56. A method for providing erythropoietin therapy to a mammal comprising administering 10. A method for providing erythropoietin an effective amount of a polypeptide according therapy to a mammal comprising administering to claims 1, 16, 39, 40 or 41. an effective amount of a pharmaceutical composition of claim 9. 57. A method according to claim 56 wherein the therapy comprises enhancing 11. A method for treating a kidney dialysis hematocrit levels. patient which comprises administering a pharmaceutical composition of claim 9 in an amount effective to increase the hematocrit level of said patient. 12. A pharmaceutical composition comprising an effective amount of a glycoprotein product effective for erythropoietin therapy according to claim 7 and a pharmaceutically acceptable diluent, adjuvant or carrier. 13. A method for providing erythropoietin therapy to a mammal comprising administering an effective amount of a pharmaceutical composition of claim 12. 14. A method for treating a kidney dialysis patient which comprises administering a pharmaceutical composition of claim 12 in an amount effective to increase the hematocrit level of said patient.

Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.


Why Is My Information Online?